Literature DB >> 15796212

Inhibition by Moxa smoke of NO production and iNOS expression in mouse macrophage-like cells Raw 264.7.

Hisatoshi Matsumoto1, Jun Shimada, Hiroshi Nagasaka, Isao Matsumoto, Ken Hashimoto, Hiroshi Sakagami.   

Abstract

The biological activities of Moxa, used as moxibustion, have not been well documented. We investigated the effect of Moxa smoke on nitric oxide (NO) production by mouse macrophage-like Raw 264.7 cells. Moxa smoke failed to stimulate the Raw 264.7 cells to produce detectable amounts of NO, but rather inhibited the NO production by lipopolysaccharide (LPS)-activated Raw 264.7 cells. The 50% inhibitory concentration (IC50) of NO production by Moxa smoke (0.16%) was one order lower than the 50% cytotoxic concentration (CC50) (4.67%). Western blot and RT-PCR analyses demonstrated that a slightly higher concentration of Moxa is required to reduce the iNOS expression at protein and mRNA levels (IC50 = 0.99 and 2.03%, respectively). The inhibition of NO production by Moxa smoke is, thus, probably due to both the inhibition of iNOS expression and radical-scavenging activity. The present data suggest the possible anti-inflammatory effect of Moxa smoke.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15796212

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  6 in total

1.  Bibliometric Analysis of Moxibustion Research Trends over the Past 20 Years.

Authors:  Hyejin Park; In-Seon Lee; Hyangsook Lee; Younbyoung Chae
Journal:  J Clin Med       Date:  2020-04-26       Impact factor: 4.241

2.  Lung Function Decline after 24 Weeks of Moxa Smoke Exposure in Rats.

Authors:  Rui He; Li Han; Ping Liu; Hai Hu; Jia Yang; Hong Cai; Chang Huang; Lei Wang; Juntian Liu; Jian Huang; Lue Ha; Yaomeng Liu; Jihong Wu; Maoxiang Zhu; Baixiao Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-10       Impact factor: 2.629

3.  The Mechanism Study of Moxa Combustion Products on Regulating Vascular Endothelial Function in Atherosclerotic Mice.

Authors:  Huang Yueping; Yao Qin; OuYang Xiali; Lin Yao; Liu Yajie; Huang Chang; He Rui; Hui Xin; Wang Hao; Zhang Rui; Liu Jinyi; Zhao Baixiao
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-03       Impact factor: 2.650

4.  How does moxibustion possibly work?

Authors:  Jen-Hwey Chiu
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-27       Impact factor: 2.629

5.  Safety recommendations for moxa use based on the concentration of noxious substances produced during commercial indirect moxibustion.

Authors:  O Sang Kwon; Seong Jin Cho; Kwang-Ho Choi; Sun Hee Yeon; Suk-Yun Kang; Jae-Hyo Kim; Seong-Hun Ahn; Yeonhee Ryu
Journal:  Acupunct Med       Date:  2016-08-11       Impact factor: 2.267

6.  Analysis of the Components in Moxa Smoke by GC-MS and Preliminary Discussion on Its Toxicity and Side Effects.

Authors:  Xiaoyu Xu; Si Shan; Wenlei Wang; Hongning Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-31       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.